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Bevacizumab (Avastin) has rapidly gained status as a broadly active agent for malignan-
cies of several different histologies in adults. This activity has spawned a range of uses
in pediatrics for both oncologic and non-oncologic indications. Early analyses indicate that
pediatric cancers exhibit a spectrum of responses to bevacizumab that suggest its activity
may be more limited than in adult oncology. Most exciting, is that for low-grade tumors
that threaten vision and hearing, there is not only evidence for objective tumor response
but for recovery of lost function as well. In addition to oncological indications, there is a
range of uses for non-oncologic disease for which bevacizumab has clear activity. Finally, a
number of mechanisms have been identified as contributing to bevacizumab resistance in
cancer. Elucidating these mechanisms will guide the development of future clinical trials
of bevacizumab in pediatric oncology.
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INTRODUCTION
Angiogenesis, or the formation of new blood vessels from pre-
existing vessels is essential for normal organogenesis and tumori-
genesis. The wide range of requirements for new blood vessel
growth during development and in the setting of pathology is
served by numerous angiogenic factors that recruit endothelial
progenitors and other pro-angiogenic and vascular supporting
cells, and promote endothelial cell proliferation and survival.
Vascular endothelial growth factor (VEGF) is essential to both
normal and pathology-associated angiogenesis and consequently,
VEGF antagonism is the primary focus of anti-angiogenic thera-
pies. Multiple isoforms of VEGF are generated through alternate
splicing and post-translational modifications of the products of
a multi-gene family comprised of VEGF-A, -B, -C, -D and pla-
centa growth factor (Ferrara, 2004). Most of the VEGF angiogenic
activity in normal and pathological conditions can be ascribed
to VEGF-A (Leung et al., 1989). VEGF-A (VEGF) expression is
regulated by hypoxia (Goldberg and Schneider, 1994) through
a HIF-1 dependent mechanism (Ema et al., 1997), as well as
by a large number of secreted hormones and cytokines that
provide for tissue specific and physiologically appropriate angio-
genic responses (Ferrara, 2004). Several primary oncogenic events
including, mutational activation of the Ras (Grugel et al., 1995)
and Wnt (Zhang et al., 2001) pathways, also upregulate VEGF
expression and VEGF is known to be overexpressed in many types
of cancer including colon cancer, non-squamous non-small cell
lung cancer (NSCLC), kidney cancer, and brain cancers. In brain
tumors, VEGF is highly expressed by both tumor cells and tumor-
associated vascular endothelial cells (Takahashi et al., 1995; Fidler,
2001; Huber et al., 2001; Salmaggi et al., 2003; Norden et al., 2008).
The resultant neovasculature provides circulatory support for
tumor growth and is thought to be important as a tumor stem cell
niche and a conduit for tumor invasion and metastasis (Takahashi
et al., 1995; Fidler, 2001). Thus, molecular inhibition of VEGF is
an attractive model for targeting tumor growth and spread.
Biological activity of VEGF is further regulated through the
generation of alternate splice forms, their post-translational mod-
ification and their sequestration, and release from cell surface and
extracellular matrix heparin sulfate binding sites. Four primary
alternately spliced isoforms of VEGF are produced (VEGF121,
VEGF165, VEGF189, VEGF206) (Houck et al., 1992). These dif-
fer in their affinities for heparin sulfate proteoglycans (HSPGs)
and thus the extent to which they are freely diffusible. VEGF121
does not bind HSPGs while VEGF189 and VEGF206 are restricted
in their diffusion by high affinity interactions with HSPGs.
VEGF165 exhibits intermediate affinity and diffusibility. Genetic
studies indicate that VEGF-HSPG interactions are required for
establishing VEGF gradients and normal angiogenesis (Carmeliet
et al., 1996; Ruhrberg et al., 2002). Proteolytic processing of
VEGF by plasmin (Keyt et al., 1996) and MMPs (Lee et al.,
2005) further regulates its interactions with HSPG and biological
activity.
Vascular endothelial growth factor binds two receptor tyrosine
kinase VEGFR-1 and VEGFR-2 (KDR) as well as two co-receptor,
Neurophilin 1 and 2. While binding to VEGFR-1 occurs with
higher affinity than binding to VEGFR-2, it is VEGFR-2 that
mediates the pro-angiogenic effects of VEGF on endothelial cells
(Olsson et al., 2006). Thus, antagonism of VEGF can be achieved
by blocking its bioavailability or by inhibiting its actions through
VEGFR-2.
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In 2004, bevacizumab, a monoclonal antibody directed at all
five isoforms of VEGF, was FDA approved to treat NSCLC and
has since been approved to treat metastatic colorectal cancer,
metastatic kidney cancer, and glioblastoma (GBM) in patients
who had progressed after prior treatment (Cohen et al., 2007a,b,
2009). It was the first drug developed to exclusively inhibit
angiogenesis. Encouraging data from adult studies has led to
an increased use of bevacizumab in the pediatric population
(Bokstein et al., 2008; Buie and Valgus, 2008; Narayana et al.,
2009). In this article, we will review the current clinical appli-
cations of bevacizumab in pediatrics and proposed mechanisms
of resistance.
BRAIN TUMORS
HIGH-GRADE GLIOMAS
Outcomes for children with high-grade gliomas (HGG) remain
dismal with 5-year-survival rates of 5–15% for grade IV gliomas
and 20–40% for grade III gliomas (Mueller and Chang, 2009;
Narayana et al., 2010). HGG characteristically posses high levels
of VEGF expression making bevacizumab, a attractive therapeutic
option (Oehring et al., 1999; Narayana et al., 2009; Keunen et al.,
2011). Several adult studies demonstrated increased progression-
free survival (PFS) and overall survival (OS) in patients with GBM
treated with bevacizumab (Bokstein et al., 2008; Buie and Valgus,
2008; Kreisl et al., 2009; Narayana et al., 2009). This encouraging
data stimulated VEGF use in pediatric patients. Multiple initial
reports described bevacizumab (10 mg/kg every other week) with
and without irinotecan (125 mg/kg every other week) in small
series of 3–12 patients with mixed diagnoses of recurrent or refrac-
tory tumors. In all cases, initial responses were evident in a subset
of patients with variable impact on survival (Carmeliet et al., 1996;
Keyt et al., 1996; Ruhrberg et al., 2002) (see Table 1). The largest
retrospective review by Couec et al. (2012) involved 28 pediatric
patients with recurrent or refractory brain tumors treated with
bevacizumab and irinotecan. Ten out of 12 patients with HGG
had a median PFS of 8 weeks and the authors concluded that
more prospective trials would be necessary to determine efficacy
in patients with HGGs (Couec et al., 2012). In 2010, the only
prospective clinical trial results for children with HGG were pub-
lished by the Pediatric Brain Tumor Consortium (Gururangan
et al., 2010). The study included 31 patients, 15 with GBM and
16 with diffuse intrinsic pontine glioma (DIPG); all were treated
with bevacizumab (10 mg/kg/dose) and irinotecan (125 mg/m2
increased to 150 mg/m2 as tolerated or 250 mg/m2 increased to
350 mg/m2) every 2 weeks. Fifteen of the patients had no objec-
tive sustained response. Eight of the patients with GBM had stable
disease for ≥12 weeks with a median of 176 days and median PFS
of 4.2 months. Median PFS for patients with DIPG was 2.3 months.
This study concluded that there is a lack of efficacy of combined
bevacizumab and irinotecan in children with recurrent GBM
and DIPG.
LOW-GRADE GLIOMAS
Low-grade gliomas (LGG) are the most common childhood brain
tumor. Treatment varies as a function of age and tumor loca-
tion between surgical resection alone, or combined surgery and
chemo or radiation therapy. Common indications for adjuvant
therapy include recurrence in surgically inaccessible locations and
threats to function particularly for deep-seated midline tumors
growth of which can result in vision loss, or hypothalamic or
brainstem dysfunction. While LGG are slow growing, biologi-
cally benign tumors, they possess increased vasculature (Plate
et al., 1992; Takahashi et al., 1995; Oehring et al., 1999) and thus
are also an attractive indication for anti-angiogenic therapy. In
2009, Packer et al. (2009) conducted a retrospective review of 10
pediatric patients with recurrent LGG, 3 with NF1, treated with
bevacizumab (10 mg/kg/dose) and irinotecan (125 mg/m2/dose)
every 2 weeks. Seven had a radiographic response (1 CR, 3
PR, and 3 minor response) and seven had clinical improve-
ment [improvement in visual acuity (n= 2), improved hemipare-
sis (n= 2), weight gain with improved diencephalic syndrome
(n= 4), decreased seizure activity (n= 2), and reversal of psy-
chomotor retardation (n= 2)]. At the conclusion of the study,
eight of the nine patients had not progressed (see Table 2). In
2012, Hwang et al. (2013) extended the Packer et al. report with
a retrospective review of 14 children (10 of whom were included
Table 1 | Efficacy results for high-grade glioma.
Study Benesch et al. (2008) Narayana et al. (2010) Parekh et al. (2011) Couec et al. (2012) Gururangan et al. (2010)
Patient
number
n=3 n=10 HGG; n=2
DIPG
n=8 n=10 HGG n=15 HGG; n=16 DIPG
Treatment Bevacizumab±other
agent
Bevacizumab and
irinotecan
Bevacizumab±other agent Bevacizumab and
irinotecan
Bevacizumab and
irinotecan
Imaging Initial tumor SD or
PR but eventual
progression
No CR Contrast enhancing lesions – PR
or SD in five of seven patients
10 of 12 PD (median
8 weeks post start of
treatment)
No SD
25% had PR on MRI
perfusion
Non-contrast enhancing lesions –
PD in three of four patients
2 SD
Median PFS
and OS
PFS 2.25 months PFS 15 weeks PFS 8 weeks PFS 4.2 months (HGG)
OS 6.35 months OS 30.5 weeks PFS 2.3 months (DIPG)
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Table 2 | Efficacy results for low-grade glioma, NF2, and other CNS malignancies.
Disease LGG LGG LGG Schwannoma
with NF2
Schwannoma
with NF2
Ependympoma Medulloblastoma
Study Packer et al.
(2009)
Hwang et al. (2013)
(includes data from
Packer et al., 2009)
Couec et al.
(2012)
Plotkin et al.
(2009)
Mautner et al.
(2010)
Gururangan
et al. (2012)
Aguilera et al.
(2011)
Number n=10 n=14 N =7 N =10 N =2 N =15 N =2
Treatment Bevacizumab
and irinotecan
Bevacizumab±
other
Bevacizumab
and irinotecan
Bevacizumab Bevacizumab Bevacizumab
and irinotecan
Bevacizumab and
irinotecan or
temozolomide
Imaging 1 CR; 3 PR; 3
minor response
12 PR; 2 SD 6 of 7 PR 6 PR; 3 SD Decreased tumor
size and resolution
of brainstem
compression.
No objective
response; 2
SD
CR in both patients
Clinical
Outcome
Improved visual
acuity (n=2),
improved
hemiparesis
(n=2), weight
gain with
improved
diencephalic
syndrome
(n=4),
decreased
seizure activity
(n=2), and
reversal of
psychomotor
retardation
(n=2)
Improved vision
(n=4), improved
ataxia (n=2),
improved
hemiparesis (n=1)
Data not
available
Improved
hearing and
word
recognition
(n=4).
Improved
headaches and
vomiting (n=1).
Decline in word
recognition
despite tumor
shrinkage
(n=1). Stable
hearing despite
tumor shrinkage
(n=1)
First patient: slight
improvement in
hearing and word
recognition.
Improved ability to
communicate over
the phone and
distinguish voices.
Data not
available
Excellent
quality-of-life
Second patient: no
improvement in
clinical hearing per
patient self-report
Median
PFS and
OS
Eight of nine
had not
progressed at
conclusion of
study
None progressed
on treatment. Time
to progression after
stopping treatment
ranged from 4 to
16 months (n=13).
14th patient was
progression-free at
45 months
All alive 1 of 6
PD
All alive All alive PD in 10
patients
(median time
2.2 months).
6-month PFS
overall 25.7%
First patient: stable
at 35 months;
therapy
discontinued after
24 months. Second
patient: malignant
cells in CSF after
18 months
in the study by Packer et al.) with multiple recurrent LGGs treated
with bevacizumab-based therapy for at least 12 months, at least
1 year out from completion of therapy. Most were treated with
bevacizumab 10 mg/kg and irinotecan 125 mg/m2 every 2 weeks;
one was treated with bevacizumab alone every 3 weeks. After
two cycles, 12 of 14 patients had an objective response and two
had stable disease. Metastatic disease responses generally corre-
lated with primary tumor response. Four patients had improved
vision, two had improved ataxia, one had improved hemiparesis,
four had weight gain with diencephalic syndrome, and three had
improved developmental milestones. No difference in response
was seen between grade I and grade II tumors. Four patients were
retreated with bevacizumab when they progressed clinically or
radiographically after the discontinuation of bevacizumab. All had
clinical or radiographic improvement while on therapy, however,
all progressed when bevacizumab was discontinued. Two received
a third treatment course; one of these patients had NF1 and had
significant improvement of vision with every treatment course
that would worsen each time it was stopped. Progression occurred
after discontinuation of therapy in 13 of 14 (range 4–16 months).
The 14th patient was progression-free at 45 months. Significant
responses to bevacizumab in children with LGG is consistent
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with reported activity for other anti-angiogenic therapies such as
thalidomide-based regimens (Short et al., 2001; Gilheeney et al.,
2007) or weekly vinblastine (Lafay-Cousin et al., 2005) and suggest
that anti-angiogenic therapy is an effective approach to treatment
of any patient with LGG requiring adjuvant therapy. Particularly
exciting is the observed improvement in vision with bevacizumab
treatment.
NEUROFIBROMATOSIS TYPE 2
Bilateral vestibular Schwannomas are a frequent and highly mor-
bid complication of Neurofibromatosis type 2 (NF2). Although
benign, these tumors tend to inexorably progress and often result
in loss of all functional hearing by middle age. Standard treat-
ment includes surgery and radiation however, these approaches
are frequently ineffective at preserving hearing (Briggs et al., 1994;
Mautner et al., 2010). Schwannomas express VEGF and the VEGF-
1 receptor; and higher levels are associated with increased rates of
tumor growth (Plotkin et al., 2009).
In 2009, Plotkin et al. conducted a retrospective study of 10
patients with NF2 (ages 16–53) treated with bevacizumab (5 mg/kg
every 2 weeks for 12 months) (Di Tomaso et al., 2011). On imag-
ing, 6 of the 10 had partial response and 3 has stable disease
(median response 26% reduction, range 44% shrinkage to 32%
growth). Of the six, four remained stable 11–16 months later (see
Table 2). There was a strong correlation between mean appar-
ent diffusion coefficient (ADC) at baseline within the tumor and
percent decrease in volume at 3 months (p= 0.001). Importantly,
four of the seven evaluable patients had 57% improvement in
word recognition beginning approximately 8 weeks after initia-
tion of therapy and four of those five also reported improve-
ment in tinnitus. Mautner et al. (2010) reported two cases where
bevacizumab had similar benefits for patients with NF2 and
vestibular Schwannomas (see Table 2). Similar to the experience
in optic pathway gliomas, these studies are particularly com-
pelling for the recovery of function observed with bevacizumab
treatment.
OTHER CNS TUMORS
Ependymomas are also associated with VEGF expression and the
level of VEGF is correlated with prognosis providing a rationale for
bevacizumab treatment (Korshunov et al., 2012). In 2012, the Pedi-
atric Brain Tumor Consortium reviewed the use of bevacizumab
and irinotecan in 15 patients with recurrent ependymoma (one
unevaluable) (Gururangan et al., 2012). No patient had a sus-
tained objective response (see Table 2). Two patients had stable
disease (12 and 10 months) and an additional patient had stable
disease at 4 months but was removed from study. The study con-
cluded that combination of bevacizumab and irinotecan was not
efficacious for the treatment of ependymoma. This is in contrast
to reports of more durable responses to a thalidomide-based anti-
angiogenic regimen for relapsed ependymoma (Gilheeney et al.,
2007).
Two patients with recurrent medulloblastoma treated with
bevacizumab and irinotecan or temozolomide were described
in a report by Aguilera et al. (2011) (see Table 2). The
first patient was a 7-year-old with anaplastic medulloblas-
toma with a spinal lesion who had a persistent spinal lesion
upon completion of therapy. After 20 months of treatment with
bevacizumab, irinotecan, and temozolomide, her brain MRI
showed a complete response and her spine MRI was stable.
She remains stable at 35 months. The second patient was a
5-year-old also with metastatic medulloblastoma who devel-
oped new leptomeningeal disease 6 months post-completion of
therapy. He was treated with bevacizumab and irinotecan and
6 months after starting treatment MRI showed complete response.
Unfortunately, 12 months later, he had malignant cells in the
CSF.
Together these studies indicate that the use of bevacizumab
remains a potential option for pediatric brain tumors of multiple
histologies but requires more complete evaluation in prospective
clinical trials.
NON-CNS MALIGNANCIES
Given the potential effectiveness in solid tumors, there have been
a few pediatric retrospective studies looking at the use of beva-
cizumab in non-CNS solid tumor malignancies. In 2008, Benesch
et al. (2008) conducted a retrospective study in compassionate
used of bevacizumab in pediatric patients (See Table 3). Three
patients with carcinomas had no stabilization of disease. Two
patients with Stage IV neuroblastoma were treated with therapy
that included bevacizumab after progression on initial therapy.
In one patient, treatment with bevacizumab, carboplatin, and
irinotecan resulted in sufficient regression of lesions that com-
plete resection was possible and the patient is in complete remis-
sion. The second patient had bone marrow relapse 13 years after
diagnosis. He was treated with bevacizumab but died prior to
evaluation.
Of the two patients with nephroblastoma, one had stable lung
metastases for 7 months after bevacizumab treatment, and then
progressed. The second patient had stabilized abdominal and
mediastinal metastases for 6 months after treatment with beva-
cizumab and topotecan, but then developed refractory malignant
ascites and treatment was stopped to avoid thromboembolic events
(Benesch et al., 2008).
Three patients with sarcomas were treated with bevacizumab
and topotecan. Two of these progressed shortly after starting treat-
ment, one with multifocal relapse of alveolar rhabdomyosarcoma
and another with parathyroidal synovial sarcoma. A patient with
pleomorphic rhabdomyosarcoma had a partial response, but sadly,
committed suicide 9 months into therapy. One patient with von
Hippel–Lindau was treated with bevacizumab and interferon-
alpha2a for a C4 spinal cord lesion for 12 months and is currently
stable (Benesch et al., 2008).
In 2004, Conde et al. (2011) reported the use of bevacizumab
as pre-operative management of alveolar soft-part sarcoma of
the tongue. Given the hemorrhagic nature of the tumor, anti-
angiogenic therapy was used prior to surgery in attempt to
reduce the mass to avoid a tongue amputation. After six cycles,
tumor size decreased by 30% and she successfully underwent
left hemiglossectomy. Three years later, she has not had reoc-
currence. In 2008, bevacizumab was used to treat a 14-year-old
female with papillary renal cell carcinoma, locally advanced, unre-
sectable who progressed after 10 months of IL-2 therapy (Joshi
and Banerjee, 2008). CT showed a partial response after six
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Table 3 | Efficacy results for non-CNS malignancies.
Study Benesch
et al. (2008)
Conde
et al. (2011)
Joshi and Baner-
jee (2008)
TumorType Carcinoma
(n=3)
Stage IV
neuroblastoma
(n=2)
Nephroblastoma
(n=2)
Sarcomas (n=3) C4 spinal cord
lesion with von
Hippel–Lindau
(n=1)
Alveolar
soft-part
sarcoma of
tongue (n=1)
Papillary renal cell
carcinoma (n=1)
Treatment Bevacizumab,
carboplatin
and irinotecan
Bevacizumab and
topotecan
Bevacizumab and
topotecan
Bevacizumab
and interferon-
alpha2a
Bevacizumab
and celexocib as
pre-operative
therapy
Bevacizumab
Outcome No SD Patient 1:
CR-lesions
decreased and
were resected.
Patient 2: died
prior to
evaluation
Patient 1: stable
lung metastases
for 7 months,
then progressed.
Patient 2: SD for
6 months, then
developed ascites
and treatment
was stopped to
avoid
thromboembolic
events
Alveolar
rhabdomyosarcoma:
progressed after
6 weeks;
pleomorphic Rhab-
domyosarcoma: PR
but committed
suicide after
9 months;
parathyroid synovial
sarcoma: progressed
after 4 months
Treated for
12 months and
currently
stable
Tumor size
decreased by
30%, able to
resect. No
reoccurrence
3 years later
After 18 months
of treatment, no
increased update
on FDG-PET. No
reoccurrence at
8 months after
surgery
treatments (10 mg/kg every 2 weeks). After 18 treatments, she
had no increased uptake on FDG-PET; no tumor reoccurrence
at 8 months after surgery.
Thus, anecdotal evidence suggests there may be specific diag-
noses like neuroblastoma and circumstances, including pre-
surgical management where bevacizumab therapy may be a benefit
in the treatment of children with cancer.
MALIGNANCY-RELATED USES
RADIATION NECROSIS
Several studies in adult patients have shown a benefit for beva-
cizumab treatment in the management of post-cranial radiation
edema, which can be a significant cause of morbidity in brain
tumor patients (Gonzalez et al., 2007; Wong et al., 2008; Matuschek
et al., 2011). In 2007, Gonzalez et al. (2007) conducted a retro-
spective review of brain tumor patients treated with bevacizumab.
All of the patients with radiation necrosis (n= 8) had a signifi-
cant reduction in both MRI fluid-attenuated inversion-recovery
(FLAIR) and T1-post-Gd contrast abnormalities. The average
daily dexamethasone dose was reduced by 8.6 mg. A retrospective
review at Children’s Hospital of Denver evaluated the response to
bevacizumab of patients with DIPG (n= 4) (Liu et al., 2009). In
each case, patients suffered clinical decline post-irradiation asso-
ciated with MRI studies consistent with edema or necrosis rather
than tumor progression. Each had initial responses to Decadron
and exhibited further improvement with bevacizumab. The com-
bined adult and pediatric experiences would support the use of
bevacizumab for the management of post-irradiation edema espe-
cially in circumstances where the toxicities of Decadron therapy
need to be minimized.
Bevacizumab may also have a role in the treatment of cap-
illary leak syndrome (CLS), a severe complication of allogeneic
stem cell transplantation. Yabe et al. (2010) reported that beva-
cizumab treatment produced rapid improvement of CLS in a
6-year-old male with Fanconi anemia after mismatched unre-
lated donor stem cell transplant. Sixty-eight days post transplant,
he developed CLS, unresponsive to prednisolone, ulinastatin, and
albumin. He was then treated with bevacizumab, 5 mg/kg. On day
1, he had improved urine production, blood pressure, and central
venous pressure. On day 2, all symptoms resolved. On day 5, he
had marked decrease in pleural effusion on CT. He had complete
resolution of CLS by day 20.
Vascular endothelial growth factor is a potent inducer of vas-
cular permeability. Blocking it in patients with severe edema such
as radiation necrosis and CLS may benefit some patients. Further
studies are needed to further evaluate these findings.
NON-MALIGNANT USES
ANGIOMATOSIS
Bevacizumab has been used in several case reports of patients
with angiomatosis, a neoplasm-like entity. Smith et al. (2008)
reported the use of bevacizumab in an infant with cutaneovisceral
angiomatosis with thrombocytopenia (CAT) syndrome,a very rare
vascular disorder associated with skin and GI lesions and throm-
bocytopenia. There is no standard of care, although therapy often
includes steroids and several agents with known anti-angiogenic
activity including vincristine, interferon-alpha2A, and thalido-
mide. In this report, a 7-month-old was treated with bevacizumab
for persistent life-threatening GI bleeds which resolved after three
doses. Kline and Buck reported a similar case in a patient with
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multifocal lymphangioendotheliomatosis with thrombocytopenia
(MLT, also known as CAT syndrome) (Kline and Buck, 2009). This
patient presented at 8 weeks of life and had multiple GI bleeds
despite vincristine, prednisolone, and thalidomide. At 2 years-of-
age, she began bevacizumab treatment and subsequently, has only
had one GI bleed.
Bevacizumab has also been reported to benefit a patient with
multifocal lymphangiomatosis or Gorham–Stout disease (GSD),
presenting as idiopathic osteolysis of the bones. GSD is possibly
triggered by occult neoplastic cells that produce large amounts of
IL-6 and VEGF. Grunewald et al. (2010) reported a 2-year-old with
GSD who continued to have progressive osteolysis with massive
pleural effusions despite PEG-interferon-alpha-2b, bisphospho-
nates, and imatinib. Progression of osteolysis and he had no further
pleural effusions resolved with the initiation of bevacizumab. He
has been stable for 27 months.
OTHER
Childhood ophthalmologic disease such as retinopathy of pre-
maturity (ROP), choroidal neovascularization (CNV), Coat’s dis-
ease, and familial exudative vitreoretinopathy can lead to severe
vision loss. Vision loss can occur for many reasons, including
retinal ischemia and VEGF-induced neovascularization and vas-
cular leakage of fluid, blood, and exudates. Mintz-Hittner et al.
(2008) conducted a multicenter prospective, randomized control
trial to assess intravitreal bevacizumab in infants with zone I or
zone II posterior stage 3+ ROP. One hundred fifty infants were
randomized to receive bevacizumab or laser therapy bilaterally.
Recurrence was seen in only 6 out of 140 eyes in the bevacizumab
group and 32 of the 146 eyes in the laser group (p= 0.002). Treat-
ment of ROP with bevacizumab is now the standard of care at
many centers. Albini and Murry reported a retrospective, non-
comparative, open-label, interventional case series in 35 eyes of 33
patients with diseases such as CVN, Coat’s disease, familial exuda-
tive vitreoretinopathy and sickle cell retinopathy who were treated
with bevacizumab (Sisk et al., 2010). Significant improvement in
visual acuity was seen in patients with excess fluid after one or
more injections (p< 0.05). One patient with sickle cell retinopa-
thy and central retinal vein occlusion had significant improvement
in central macular thickness over 6 months after one injection
(811–56µm). Similar effectiveness was also reported for treat-
ment of CNV after Stevens–Johnson syndrome (Kesarwani et al.,
2012).
Maturo and Hartnick (2010) reported the use in three children
with severe recurrent respiratory papillomatosis. Bevacizumab
was thought to be indicated based on increased VEGF receptor
expression in pediatric laryngeal papilloma specimens (Rahbar
et al., 2005). All three showed an increased time between sur-
gical interventions and two of the three had improvement on
quality-of-life scores.
ADVERSE EVENTS
In adult studies, serious adverse events have been reported with the
use of bevacizumab including CNS hemorrhage (1–5%), hyper-
tensive crisis (<1%), and blood clots (6–9%) (Scappaticci et al.,
2007; Nalluri et al., 2008; Marion, 2013). Such risks have made
some pediatric practitioners wary of treating with bevacizumab.
Fortunately, these events have rarely been reported in children.
Multiple retrospective studies reviewed adverse events reported in
pediatric patients treated with bevacizumab and no study reported
intracerebral hemorrhage, stroke, or thrombosis (see Table 4)
(Glade Bender et al., 2008; Joshi and Banerjee, 2008; Packer et al.,
2009; Gururangan et al., 2010; Mautner et al., 2010; Narayana
et al., 2010; Reismüller et al., 2010; Di Tomaso et al., 2011; Parekh
et al., 2011; Couec et al., 2012; Hwang et al., 2013). In 2008, the
Children’s Oncology Group conducted a prospective Phase I trial
of bevacizumab in pediatric patients with solid tumors (Glade
Bender et al., 2008). In this trial, there were no dose-limiting
toxicities, no need to discontinue therapy, and no reports of hem-
orrhage or thrombosis. The most common adverse events reported
were Grade I and Grade II events including elevated blood pres-
sure (not typically requiring medical management), proteinuria,
lymphopenia, epistaxis, and delayed wound healing. The most
commonly reported Grade III events were hypertension (HTN)
and proteinuria. Other less common Grade III events included
fatigue, poor wound healing, lethargy, transient joint pain, lym-
phopenia, and pneumonia. Grade IV events were even less com-
mon but a few were reported (all n= 1) including anaphylaxis,
cerebral ischemia, posterior reversible encephalopathic syndrome,
proteinuria, lymphopenia, and pneumonia.
In the cases reported by Hwang et al. (2013) who were retreated
with bevacizumab, there were no reported events higher than
Grade II, however, they did tend to occur sooner and result in
stopping treatment in three of the four patients (due to epis-
taxis, proteinuria, HTN, primary inflammatory arthritis, ptery-
goid myositis). HTN, joint pain, and proteinuria improved with
increasing dosing interval. Most resolved within 1 month of stop-
ping treatment. Two cases of HTN and proteinuria took several
months to resolve. One patient had persistent grade 2 HTN 1 year
after completion of therapy.
In patients with NF2 treated with bevacizumab at 5 mg/kg/dose,
no thromboembolic events, hemorrhage, congestive heart fail-
ure, gastrointestinal perforation, reversible posterior leukoen-
cephalopathy, or Grade III/IV events have been reported (Plotkin
et al., 2009; Mautner et al., 2010). Grade I/II events reported were
similar to those reported in patients treated at higher doses of
bevacizumab.
Secondary amenorrhea was reported in a few patients. In the
Phase I COG study, two of three post-menarchal females had a rise
is LH and FSH, one subsequently missed her periods (Glade Ben-
der et al., 2008). In the patient treated for renal cell carcinoma who
developed amenorrhea, menses resumed 1 month after cessation
of bevacizumab (Joshi and Banerjee, 2008).
The patient treated for CAT syndrome was noted to have
multiple punched out boney lesions after four doses of beva-
cizumab (Smith et al., 2008). Bevacizumab was stopped and repeat
imaging 2 months later showed complete resolution of the bony
lesions.
Together, these studies indicate that bevacizumab is gener-
ally well tolerated in the pediatric population at doses up to
15 mg/kg/dose. Serious side effects seen in adults have not been
reported in the pediatric population.
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MECHANISMS OF RESISTANCE
Targeting VEGF pathways clearly has a role in the treatment of
a broad range of human disease. Some applications, like the
treatment of post-irradiation edema or CLS, relate more to VEGF-
mediated regulation of vascular permeability rather than to VEGF-
stimulated angiogenesis. In these circumstances bevacizumab has
demonstrated significant effect and it is likely that its use as a single
agent for these indications will increase. In contrast, as detailed
above, in cancer treatment when the angiogenic functions are
the critical target for VEGF directed therapies, bevacizumab fails
in most cases to produce a lasting clinical response. Identifying
the mechanisms of resistance and appropriately modifying treat-
ment approaches will be essential for the full realization of the
potential of anti-angiogenic therapies. Here we will briefly review
proposed mechanisms by which cancers adapt and evade VEGF
antagonism.
In discussion of and investigation into mechanisms of beva-
cizumab resistance, much has been made of an apparent change in
the pattern of recurrence in bevacizumab-treated, versus conven-
tionally treated, GBM. Some retrospective and prospective studies
have reported an increase in the frequency of diffuse and distant
recurrence after bevacizumab therapy from approximately 10–
50% (Norden et al., 2008; Narayana et al., 2012a,b). However, these
conclusions have been called into question by several additional
studies that indicate the prevalence of pathologically identified
disseminated disease at GBM recurrence in the pre-bevacizumab
era is really 17% (Silbergeld et al., 1991) and the pattern of dissem-
inated disease after bevacizumab treatment to be no different from
this or from recurrence without bevacizumab treatment (Cham-
berlain et al., 2009; Pope et al., 2009). Preclinical models however,
do support a shift in GBM growth from what has been termed
an expansile to a permeative pattern to reflect its highly invasive
nature (Pàez-Ribes et al., 2009; de Groot et al., 2010; Keunen et al.,
2011).
The mechanisms that drive resistance to bevacizumab ther-
apy are not yet fully defined. However, preclinical and clinical
studies have revealed multiple intratumoral and systemic path-
ways that can contribute to tumor progression on bevacizumab
therapy and these have been well reviewed by Bergers and Hana-
han (2008). In response to bevacizumab-induced hypoxia, model
tumors can increase expression of pro-angiogenic factors like
FGFs 1 and 2 (Casanovas et al., 2005). Moreover, systemic up-
regulation of FGF as well as the pro-angiogenic factor CXCL12
has also been observed in patients treated with the VEGF receptor
inhibitor Cediranib (Batchelor et al., 2007). In addition, beva-
cizumab therapy is associated with recruitment of pro-angiogenic
bone-marrow-derived cells that can directly participate in angio-
genesis or provide support and protection for already formed
blood vessels through the elaboration of pro-angiogenic cytokines
(Song et al., 2005; Jin et al., 2006; Du et al., 2008; Shaked et al.,
2009; Kioi et al., 2010). Finally, the potential for vascular mimicry
and the transdifferentiation of glioma stem cells into endothelial-
like cells may be an important mechanism for VEGF-independent
angiogenesis (Ricci-Vitiani et al., 2010; Wang et al., 2010; Dong
et al., 2011; Scully et al., 2012). It is likely that the relative con-
tributions that each of these mechanisms makes to bevacizumab
and other anti-angiogenic therapies as well as the specific circum-
stances in which each is most active will need to be enumerated
before fully successful anti-angiogenic therapies for malignancies
can be realized.
FUTURE DIRECTIONS
In addition to developing therapeutics that can target the multiple
mechanisms of angiogenesis and tumor recurrence, a great clin-
ical challenge as we advance anti-angiogenic therapies for cancer
will be the application of laboratory and imaging techniques that
can better define response early in therapy. This will be especially
critical in the application of anti-angiogenic therapies to brain
tumors where serial biopsy is not currently available. In this regard,
serum evaluation for the up-regulation of pro-angiogenic factors,
especially those associated with resistance like VEGF, PIGF, PDGF,
FGF, IL8, CXCL12 may provide insight into shifts in response
(Murukesh et al., 2010). Recent clinical trial data with several
anti-angiogenic tyrosine kinase inhibitors have demonstrated that
increased VEGFA and PIGF levels are associated with treatment
and reduced survival (Drevs et al., 2005; Rini et al., 2008; Bass et al.,
2010; Nikolinakos et al., 2010).
In addition, imaging, particularly MRI-based spectroscopy,
perfusion, diffusion, and oxygen consumption sequences may
be able to detect functional changes in the vasculature relevant
to anti-angiogenic responses and recurrent angiogenesis (Pope
et al., 2009, 2011; Ellingson et al., 2011; Ben Bashat et al., 2012).
As examples, Pope et al. (2012) recently published that baseline
ADC histograms are predictive of 6-month survival in patients
with recurrent GBM treated with bevacizumab and Sorensen
et al. (2012) reported that increased perfusion in recurrent GBM
patients treated with cediranib is also predictive of survival. In
addition, acute metabolic changes in response to cediranib ther-
apy are detectable with MRI-spectroscopy patients and should be
evaluated for their correlation with survival (Kim et al., 2011).
Finally, PET imaging for therapy-induced changes in expres-
sion of specific components of angiogenic pathways as well as for
changes in vascular function is an additional promising approach
for detecting response to anti-angiogenic therapies that is just
entering clinical evaluation (Chen and Chen, 2011; Schwarzen-
berg et al., 2012). Schwarzenberg et al. (2012) have reported
exciting new findings demonstrating the superiority of 3′-deoxy-
3′-18F fluorothymidine imaging to conventional MRI imaging for
detecting early response to bevacizumab therapy in patients with
recurrent GBM.
Together, sophisticated and combinatorial monitoring of
response to anti-angiogenic therapies may support the timing of
adjunctive interventions to circumvent resistance mechanisms and
enhance efficacy.
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